Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET
WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (Mustang) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host a key opinion leader (KOL) webinar on MB-106, the Companys CD20-targeted, autologous CAR T cell therapy for the treatment of B-cell non-Hodgkin lymphomas (B-NHLs) and chronic lymphocytic leukemia (CLL), on Thursday, December 16, 2021, at 2:30 p.m. Eastern Time.
The webinar will feature a presentation by Mazyar Shadman, M.D., M.P.H., Associate Professor at the Fred Hutchinson Cancer Research Center (Fred Hutch) and a physician at Seattle Cancer Care Alliance, who will discuss updated interim results from the ongoing Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 for patients with relapsed or refractory B-NHLs and CLL. These data were selected for presentation at the the 63rd American Society of Hematology Annual Meeting (ASH2021), which is being held December 11-14, 2021. Dr. Shadman, along with colleague Brian Till, M.D., also an Associate Professor at Fred Hutch and physician at Seattle Cancer Care Alliance, will be available to answer questions following the formal presentations.
Mustang Bios management team will provide additional details on the planned MB-106 Phase 1/2 clinical trial to be conducted under Mustangs Investigational New Drug (IND) application. The U.S. Food and Drug Administration accepted Mustangs IND to initiate a multicenter Phase 1/2 clinical trial investigating the safety, tolerability and efficacy of MB-106 for relapsed or refractory B-NHLs and CLL.
To register for the event, please click here.
About Dr. ShadmanMazyar Shadman, M.D., M.P.H., is an Associate Professor at the University of Washington (UW) and Fred Hutch as well as a physician at Seattle Cancer Care Alliance. He is a hematologic malignancies expert who specializes in treating patients with lymphoma and CLL.
Story continues
Dr. Shadman is involved in clinical trials using novel therapeutic agents, immunotherapy (CAR T cells), and stem cell transplant for treatment of lymphoid malignancies with a focus on CLL. He also studies the clinical outcomes of patients using institutional and collaborative retrospective cohort studies.
Dr. Shadman received his M.D. from Tehran University in Iran. He finished an internal medicine internship and residency training at the Cleveland Clinic in Cleveland, Ohio. He completed his fellowship training in hematology and medical oncology at UW and Fred Hutch. Dr. Shadman also earned an M.P.H. degree from UW and was a fellow for the National Cancer Institutes cancer research training program at Fred Hutch, where he studied cancer epidemiology.
About Dr. TillBrian Till, M.D., is an Associate Professor in the Clinical Research Division of Fred Hutch and Department of Medicine at UW as well as a physician at Seattle Cancer Care Alliance. His laboratory focuses on developing chimeric antigen receptor (CAR)-based immunotherapies for non-Hodgkin lymphoma and understanding why CAR T cell therapies work for some patients but not for others. He led the first published clinical trial testing CAR T cells as a treatment for lymphoma patients. Dr. Till also has a clinical practice treating patients with lymphoma and attends on the stem cell transplantation and immunotherapy services at the Seattle Cancer Care Alliance.
Note: Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future.
About MB-106 (CD20-targeted CAR T Cell Therapy) CD20 is a membrane-embedded surface molecule which plays a role in the differentiation of B-cells into plasma cells. The CAR T was developed by Mustangs research collaborator, Fred Hutch, in the laboratories of the late Oliver Press, M.D., Ph.D., and Brian Till, M.D., Associate Professor in the Clinical Research Division, and exclusively licensed to Mustang in 2017. MB-106 has been optimized as a third-generation CAR derived from a fully human antibody and is currently in a Phase 1/2 open-label, dose-escalation trial at Fred Hutch in patients with B-NHLs and CLL. Additional information on the trial can be found at http://www.clinicaltrials.gov using the identifier NCT03277729.
About Mustang BioMustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating todays medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (SEC). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit http://www.mustangbio.com.
ForwardLooking StatementsThis press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on managements current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Company Contacts:Jaclyn Jaffe and Bill BegienMustang Bio, Inc.(781) 652-4500ir@mustangbio.com
Investor Relations Contact:Daniel FerryLifeSci Advisors, LLC(617) 430-7576daniel@lifesciadvisors.com
Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com
- Making Blood Stem Cells on a Microchip: Academic Minute - December 27th, 2022
- Novel detection of stem cell niche within the stroma of limbus in the rabbit during postnatal development | Scientific Reports - Nature.com - August 14th, 2022
- Why Nebraska's U.S. Airmen have filed a lawsuit refusing the COVID-19 vaccine - KETV Omaha - July 27th, 2022
- Hepatic stellate cells in liver development, regeneration, and cancer - July 11th, 2022
- Fasting triggers stem cell regeneration of damaged, old immune system ... - June 13th, 2022
- Columbus man to be one of first to receive transplant via new OhioHealth program - 10TV - April 19th, 2022
- Grayson authorizes more than $1 million for ongoing and new equine research in 2022 - EQUUS Magazine - March 25th, 2022
- Cancer stem cells in glioblastoma - January 20th, 2022
- First-responder cells after heart attack prompt ... - January 20th, 2022
- New clinical trials from University Hospitals Seidman Cancer Center to begin with human protein following successful on-site approach to producing and... - December 24th, 2021
- Riverside Biologics Health Review: At Home "Stem Cells ... - December 24th, 2021
- China-bound Graduate Focused on Global Goals - University of Mary Washington - December 10th, 2021
- Fruit Cells, Space Bread, and Cultured Meat Cartridges: Deep Space Food Challenge Announces Phase 1 Winners - The Spoon - October 28th, 2021
- Fungi foray: Wild mushrooms are a key part of food chain - Farm and Dairy - August 5th, 2021
- AgeX Therapeutics Inc. (NYSE:AGE) stock surged in the premarket trading session; heres why - Market Globalist - May 13th, 2021
- University Hospitals treats first cancer patient in Ohio with "game changing" CAR T therapy - News 5 Cleveland - May 13th, 2021
- Weekly line: What the new coronavirus variants mean for vaccines, transmission, and more - The Daily Briefing - January 20th, 2021
- Forge Biologics Announces FDA Clearance of Investigational New Drug Application for Phase 1/2 Clinical Trial (RESKUE) of FBX-101 Gene Therapy for... - January 9th, 2021
- The Rise of Steve Sarkisian ... And the Decline of the Man Who Got Him Here - Sports Illustrated - January 9th, 2021
- Raleigh man delivers stem cells to patients around the world - WRAL.com - November 28th, 2020
- A real life Superman celebrates 5 years of survival from one of the deadliest cancers - Newswise - November 28th, 2020
- The Museum That Fell From the Sky | History - Air & Space Magazine - November 28th, 2020
- A Detroit Lions VP tries to avoid wasting her daughter from uncommon illness - The Shepherd of the Hills Gazette - November 28th, 2020
- US biotechnology company races to get its COVID-19 therapeutic approved for access, which has previously shown positive results in severely ill... - November 5th, 2020
- STEM CELLS - Regenerative Medicine Institute of Ohio - October 18th, 2020
- FDA Grants Orphan Drug Designation to Novel Bcl-2 inhibitor in CLL - Targeted Oncology - September 9th, 2020
- Breastfeeding 'even better than previously thought' - The Irish News - The Irish News - June 29th, 2020
- Regenerative Therapy Options for Horses With Osteoarthritis - TheHorse.com - June 12th, 2020
- Why Do Some People Get Sick All the Time, While Others Stay in Freakishly Good Health? - Discover Magazine - June 12th, 2020
- How safe are Ohio summer fun activities amid the coronavirus threat? The Wake Up for Friday, May 29, 2020 - cleveland.com - May 31st, 2020
- Kenneth Wallace Promoted to Full Professor at Clarkson University - Clarkson University News - May 31st, 2020
- ODDS AND ENDS: Melonheads and other offbeat offerings - Toronto Sun - May 31st, 2020
- OHIO researchers win grant to study treatment for possible fatal complications of COVID-19 - Huntington Herald Dispatch - May 8th, 2020
- Coronavirus Today: We're starting to reopen - Los Angeles Times - May 8th, 2020
- COMMENTARY || Pseudoscience and COVID-19we've had enough already - Folio - University of Alberta - May 3rd, 2020
- This Week in Green Tech: STEM Lessons, Solar Power and the Coronavirus, and More - ENGINEERING.com - May 3rd, 2020
- AskBio Announces First Patient Dosed in Phase 1 Trial Using AAV Gene Therapy for Congestive Heart Failure - BioSpace - February 7th, 2020
- Tune in Tonight: Oscar-nominated The Cave debuts on National Geographic - St. Augustine Record - January 25th, 2020
- Best Stem Cell Therapy Treatment in Cincinnati, Ohio ... - November 28th, 2019
- Time to Try Again: Gene-Based Therapy for Neurodegeneration - Alzforum - November 28th, 2019
- NIA Mourns the Loss of Dr. Huber Warner - National Institute on Aging - November 13th, 2019
- Research Roundup: Genomic Dark Matter Mutation and More - BioSpace - October 23rd, 2019
- Stem Cell Treatment Lima | Orthopaedic Institute of Ohio - September 10th, 2019
- Regenerative Therapy in Northeast Ohio | Ohio Therapy Centers - September 9th, 2019
- Stem cell therapy now available in central Ohio! - May 30th, 2019
- Stem Cell Therapy Clinic in Cleveland, Ohio - March 26th, 2019
- Massages & Treatments | Day Spa on Lake Erie in Ohio | The ... - March 10th, 2019
- *NEW* Regenerative Stem Cell Therapy | Ohio Therapy Centers - December 7th, 2018
- Stem Cell Therapy | Ohio Stem Cell - November 5th, 2018
- Ohio Stem Cell Treatment Center of Cleveland (Beachwood ... - November 3rd, 2018
- Conjoined twins - Wikipedia - September 20th, 2018
- Government website steers patients to unproven medical treatments - MyAJC - September 2nd, 2017
- Modern Health & Wellness of Lima institutes regenerative stem cell therapy - Lima Ohio - September 2nd, 2017
- Salk faces 'daunting' need for money despite big success with ... - The San Diego Union-Tribune - August 26th, 2017
- 'Nanotransfection' Turns Animal Skin into Blood Vessels and Brain ... - Medical Device and Diagnostics Industry - August 26th, 2017
- This Chip Uses Electricity to Reprogram Cells for Healing - Singularity Hub - August 25th, 2017
- This year's freshman class at Misericordia University is third largest in school history - The Dallas Post - August 25th, 2017
- Nanochip Could Heal Injuries or Regrow Organs with One Touch - NewsFactor Network - August 18th, 2017
- Wild new microchip tech could grow brain cells on your skin - CNET - August 8th, 2017
- Researchers explore possible alternative to knee replacement - Scope (blog) - August 5th, 2017
- Jackson Twp.'s Emmie Wanzer loves her new wheelchair swing provided by Wishes Can Happen Wanzer - Canton Repository - July 4th, 2017
- Scientists Discover That Fasting Triggers Stem Cell ... - November 23rd, 2016
- Stem-Cells | The Institute for Applied & Professional Ethics - November 18th, 2016
- Stem Cell Transplant Program - Cleveland, Ohio - October 17th, 2016
- Update: Ohio Stem Cell Study Recruiting People with MS ... - October 17th, 2016
- National Center For Regenerative Medicine - October 17th, 2016
- Stem-cell niche - Wikipedia, the free encyclopedia - October 19th, 2015
- Alex Potoczak of Ohio Praises Umbilical Stem Cell Research ... - July 2nd, 2015
- Dr. Foglietti | Ohio Stem Cell Treatment Center of Cleveland - April 27th, 2015
- Taubman Institute Receives $3 Million Wexner Gift to Support Emerging Physician-Researchers - April 3rd, 2015
- Morgan's Fund Launches Necrotizing Enterocolitis (NEC) Podcast Series: Premiere Features Dr. Gail Besner - March 24th, 2015
- Ohio Stem Cell Knee Arthritis Treatment-Regenexx - February 23rd, 2015
- We Were Promised Space Lasers: The State of the Union's Biggest Fibs - January 21st, 2015
- We Were Promised Space Lasers: State of the Union's Biggest Fibs - January 20th, 2015
- We Were Promised Space Lasers: The State of the Union's Big Fibs - January 17th, 2015
- 'Unprecedented': Drug May Help Heal Damaged Spines - December 4th, 2014
- New DNA discovery could lead to chromosome therapies in the future - November 19th, 2014
- Tiny Stomachs Grown in the Lab - October 31st, 2014
- Stem Cells Used to Grow Mini-Stomachs Seeking Treatments - October 30th, 2014
- Scientists build 'mini-stomachs' in lab - October 30th, 2014